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Title: The Era of Nanomedicine 
Journal of Pharmacy and Bioallied Sciences is now in its 7th issue and in the way that has been 
paved so far, it is possible to find some works on nanomedicine. This term encompasses the 
applications of nanotechnology in the diagnosis and treatment of diseases and comprises an 
emerging field that is believed to have the potential to revolutionise individual health in the 
present century. The outstanding approach of nanomedicine is that it offers the delivery of 
potential drugs which were previously beyond the capacities of microscale technologies, due to 
specific biological barriers. Currently, several nanotherapeutics are approved or are undergoing 
clinical trials and application of nanotechnologies is expected to extend to many more 
commercial products in the near future. 
Particularly in the case of the administration of biopharmaceuticals, a group of molecules that 
includes proteins, peptides, genes and vaccines, which discovery has been accentuated in the 
recent years, nanomedicines have been referred as a real tool to improve delivery efficacy. In 
fact, these are not exactly “new” therapeutic molecules, because hormones, serum proteins and 
enzymes have been finding therapeutic applications ever since the commercial introduction of 
insulin in 1923. However, recent progress in biotechnology, biochemical synthesis and 
molecular biology, together with the better understanding of the role of biopharmaceuticals in 
physiopathology, has attracted increasing interest over the potentialities of these biodrugs. 
Actually, some of them have successfully entered the market and play leading roles alongside 
other established therapies. Nevertheless, severe difficulties have been generally limiting their 
effective application, as these biomacromolecules exhibit two main properties that hamper their 
systemic administration, related with the high molecular weight and the strong hydrophilic 
character, thus posing a real challenge to the pharmaceutical industry in demanding 
overcoming the successive limitations imposed by their physicochemical properties.  
As recognising the need to provide non-invasive administration alternatives for new molecules 
entering the market, most of the academic and industrial efforts are being directed towards the 
development of needle-free options. It is exactly in this point that nanomedicines find their great 
pathway. With an increased surface-to-volume ratio, they display improved drug loading 
capacity, as well as evidence the ability to increase drug absorption by reducing epithelial 
resistance to transport and inclusive have shown, in occasions, the capacity to carry the 
encapsulated drugs through the epithelium. 
The first generation of nanomedicines, mainly liposomes and nanoparticles, has been entering 
routine clinical use for almost 20 years and many individuals have already benefited from their 
potentialities. Nevertheless, as the scope of nanotechnology applications in biomedicine 
evolves and nanostructures are becoming more complex, a concern is emerging and gaining 
even more importance every day, which is related to the risk-benefit balance. In fact, Kipen and 
Laskin have stated that Smaller is not always better: nanotechnology yields nanotoxicology and, 
although this is not necessarily true, because there is a lack of toxicological data on engineered 
nanomedicines that does not allow for an adequate risk assessment, it is becoming clear that 
new generation nanomedicines must build on lessons learnt from the past. The event of 
nanotoxicology is growing in importance these days and many efforts are being directed to this 
topic, in order to clarify the adequacy and safety of nanoscaled materials. It is well recognised 
that physicochemical properties of materials can alter dramatically at nanoscopic scale. As 
such, it is very important to recall that nanomedicines have new and unique biological 
properties, thus generating potential different risks as compared to the raw materials of the 
same chemistry, therefore demanding careful assessment of unexpected toxicities and 
biological interactions. In fact, with a multitude of opportunities for nanomaterials application in 
pharmaceutical and medical applications, a thorough understanding of associated systemic 
toxicity is critical. The demonstration of nanomedicines safety is indeed the necessary step for 
the great achievement of making stable effective drugs from unstable biopharmaceuticals. 
